{"id":183737,"name":"APOTEX CORP.","slug":"apotex-corp","state":"FL","country":"United States of America","description":"","totalSpending":8990000,"filings":34,"yearlySpending":[{"year":2018,"income":1520000},{"year":2019,"income":1000000},{"year":2020,"income":870000},{"year":2021,"income":900000},{"year":2022,"income":900000},{"year":2023,"income":1440000},{"year":2024,"income":680000},{"year":2025,"income":1680000}],"issues":["CPT","BUD","PHA","TRD","MMM","MAN","HCR","TAR"],"firms":["APOTEX CORP."],"lobbyists":["STEVEN GIULI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Commerce, Dept of (DOC)","Executive Office of the President (EOP)","Health & Human Services, Dept of (HHS)","Natl Economic Council (NEC)","Office of Management & Budget (OMB)","Bureau of Industry and Security (BIS)","Natl Security Council (NSC)","U.S. Trade Representative (USTR)"],"sampleDescriptions":["Federal policy relating to inter partes review challenges of pharmaceutical and biotechnology patents.","HR 1892, the Bipartisan Budget Act of 2018, related to the inclusion of S.974/HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act; and\n\nHR 1625, the Consolidated Appropriations ","Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and\n\nS. 2476, the Expanding Access t","Federal policy related to the inclusion of provisions that enhance and facilitate generic drug and biosimilar competition in a revised North American Free Trade Agreement","Federal policy related to the inclusion of provisions that enhance and facilitate generic drug and biosimilar competition in a revised North American Free Trade Agreement"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}